Bachem Holding (BHM) Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BHM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8.40 |
| 52 Week High | CHF 8.40 |
| 52 Week Low | CHF 4.60 |
| Beta | 0.81 |
| 1 Month Change | 19.15% |
| 3 Month Change | 34.40% |
| 1 Year Change | 57.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| BHM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 21.7% | 1.5% | 3.8% |
| 1Y | 57.0% | -9.6% | 3.9% |
Return vs Industry: BHM exceeded the German Life Sciences industry which returned -9.6% over the past year.
Return vs Market: BHM exceeded the German Market which returned 3.9% over the past year.
Price Volatility
| BHM volatility | |
|---|---|
| BHM Average Weekly Movement | 12.8% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: BHM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BHM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BHM fundamental statistics | |
|---|---|
| Market cap | €6.32b |
| Earnings (TTM) | €161.83m |
| Revenue (TTM) | €755.99m |
Is BHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHM income statement (TTM) | |
|---|---|
| Revenue | CHF 695.07m |
| Cost of Revenue | CHF 495.34m |
| Gross Profit | CHF 199.73m |
| Other Expenses | CHF 50.94m |
| Earnings | CHF 148.79m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 1.99 |
| Gross Margin | 28.74% |
| Net Profit Margin | 21.41% |
| Debt/Equity Ratio | 3.9% |
How did BHM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 03:20 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bachem Holding AG is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Laager | Berenberg |